EAST
WINDSOR, N.J., July 23,
2024 /PRNewswire/ -- ForDoz Pharma Corp., a private
specialty pharmaceutical company focused on product development,
manufacturing and commercialization of complex injectables, like
liposomes, microspheres, nano-suspensions, etc., today announced
the ANDA approval of DOXOrubicin Hydrochloride Liposome
Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) from the
United States Food and Drug Administration (US
FDA). DOXOrubicin Hydrochloride Liposome Injection is
indicated for the treatment of patients with ovarian cancer
and AIDS-related Kaposi's sarcoma. Doxorubicin hydrochloride
liposome injection,
in combination with bortezomib, is indicated
for the treatment of patients with multiple myeloma.
"The approval of DOXOrubicin Hydrochloride Liposome Injection
marks a major milestone for ForDoz Pharma as our
1st liposomal injectable pharmaceutical product to
enter the US market. It will be distributed by Lupin
Pharmaceuticals, Inc.," said James
He, Founder and CEO of ForDoz Pharma.
About ForDoz Pharma Corp. ForDoz Pharma
Corporation is a privately-owned specialty pharmaceutical company
focusing on development, manufacturing, and commercialization of
value-added sterile and complex injectable products. Based on its
proprietary technology platform and unique cGMP sterile
manufacturing facility, the company's corporate strategy is to
accelerate the development and manufacturing of complex injectables
for its own and help others through CDMO service.
Please visit www.fordozpharma.com for more
information
LinkedIn: www.linkedin.com/company/fordoz-pharma-corp/
Media Contact:
James He, CEO
609-469-5949
View original
content:https://www.prnewswire.com/news-releases/fordoz-pharma-corp-announces-fda-approval-of-doxorubicin-hydrochloride-liposome-injection-302204029.html
SOURCE ForDoz Pharma Corp.